Nuvectis Pharma (NVCT) is a biopharmaceutical company focused on the development of targeted therapies for the treatment of cancer.
Field:BioPharma
Status:Public (NYSE: NVCT)
Field:BioPharma
Status:Public (NYSE: NVCT)
Location: United States, New Jersey, Fort Lee
Investors 1
| Date | Name | Website |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 6
| Date | Title | Description |
| 24.07.2026 | Pharmaceutical Frontier: Psychedelics Rise, GLP-1s Diversify, Global Innovation Thrives | The pharmaceutical industry undergoes rapid transformation. Big Pharma embraces psychedelic drugs, acquiring key innovators to treat diverse mental health conditions. This signals a new era for depression, PTSD, and anxiety therapies. Concu... |
| 23.07.2026 | Haisco's Class 1 Innovative Drug Ciprocopan Succinate Tablets Approved in China, Offering a New Treatment Option for Patients With PNH | BEIJING, July 23, 2026 /PRNewswire/ -- Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the Nati... |
| 23.06.2026 | Haisco Enters into Exclusive License Agreement with Nuvectis for Two Drug Candidates in Oncology and Complement Indications | BEIJING, June 23, 2026 /PRNewswire/ -- On June 23, 2026 (Beijing time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology comp... |
| 05.02.2025 | Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock | FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet... |
| 02.10.2024 | ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City | Conference to Feature Leading Healthcare Companies and Institutional Investors for 1x1/Small Group Meetings and Panels NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via IBN -- ROTH Capital Partners, LLC (“ROTH”), www.roth.com, is pleased to a... |
| 04.10.2022 | ROTH Capital Partners to Host Inaugural Healthcare Opportunities Conference on October 6th at the Yale Club in New York City | Event to feature company presentations and one-on-one meetings between institutional investors and senior management from select Healthcare companies in Biotechnology, Pharmaceuticals, Medical Technologies, Oncology and Mental Health Therap... |